A 65-year-old woman has hypertension, dyslipidemia, type 2 diabetes, a 50 pack-year history of cigarette smoking, currently smoking ½ PPD,  and stage 3B chronic kidney disease (CKD)  (GFR = 37 mL/min/1.73 m2). She is not currently taking any dyslipidemia therapy and her LDL= 140 mg/dL. Which of the following represents the most appropriate pharmacologic intervention for treatment of dyslipidemia?

A. Owing to her age and comorbidity, no further intervention is required.

B. Moderate-intensity statin therapy is the preferred treatment option.

C. Niacin should be prescribed.

D. The use of ezetimibe (Zetia®) will likely be sufficient to achieve dyslipidemia control.

---
YouTube: https://www.youtube.com/watch?v=up_iIweB9Ic&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=27

Visit fhea.com to learn more!